ZOZhao Ou

Zhao Ou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhao Ou has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Chunxi Li

    Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, 511300 Guangzhou, Guangdong, China

    1 shared publication
  • Hangming Dong

    Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China

    1 shared publication
  • Jiangfeng Lv

    Dian Diagnostics Group Co., Ltd., 310000 Hangzhou, Zhejiang, China

    1 shared publication
  • Jianhui Xu

    Department of Respiratory Medicine, The Zengcheng Branch of Nanfang Hospital, Southern Medical University, 511300 Guangzhou, Guangdong, China

    1 shared publication
  • Shuhua Zhang

    Department of Respiratory Medicine, The Zengcheng Branch of Nanfang Hospital, Southern Medical University, 511300 Guangzhou, Guangdong, China

    1 shared publication
  • Wang Luo

    Department of Respiratory Medicine, The Zengcheng Branch of Nanfang Hospital, Southern Medical University, 511300 Guangzhou, Guangdong, China

    1 shared publication

Latest Publications

  • Open Access

    Comparison of Third-Generation Sequencing Technology and Traditional Microbiological Detection in Pathogen Diagnosis of Lower Respiratory Tract Infection

    by Wang Luo, Yanbin He, Jianhui Xu, Shuhua Zhang, Chunxi Li, Jiangfeng Lv, Youfeng Shen, Zhao Ou, Hangming Dong

    Background: It is common to obtain a low detection rate and unsatisfactory detection results in complex infection or rare pathogen detection. This retrospective study aimed to illustrate the application value and prospect of the third-generation sequencing technology in lower respiratory tract infection disease. Methods: This study recruited 70 patients with lower respiratory tract infection (LRTI). Pathogen detection of bronchoalveolar lavage fluid (BALF) from all patients was performed using nanopore metagenomic sequencing technology and traditional culture. BALF culture combined with quantitiative PCR (qPCR) was used as a reference standard to analyze the sensitivity and specificity of nanopore sequencing technology. The current study also collected the examination results of enrolled samples using technical methods sputum culture, tuberculosis DNA (TB-DNA), and Xpert MTB/RIF and analyzed the detection efficiency of nanopore sequencing for Mycobacterium tuberculosis. Results: The positive rates of pathogens in 70 BALF samples detected by conventional culture and nanopore sequencing were 25.71% and 84.29%, respectively. Among the 59 positive BALF cases using nanopore sequencing, a total of 31 pathogens were identified, of which the proportions of bacteria, fungi, viruses, and other pathogens were 50%, 17%, 32%, and 1%, respectively. Using the results combined with culture and qPCR detection methods as the standard, the pathogen detection of BALF using nanopore sequencing had a sensitivity of 70% and a specificity of 91.7%. Additionally, the positive rate of the detection of M. tuberculosis using nanopore sequencing was 33.3% (6/18). The clinical medication plans of 74.3% (52/70) of the patients were referred to the nanopore sequencing results, of which 31 cases changed their treatment strategy, 21 supported the previous treatment plans, and 90% (47/52) of the patients finally had clinical improvement. Conclusions: BALF detection using nanopore sequencing technology improves the process of detecting pathogens in patients with LRTI, especially for M. tuberculosis, fungi, and viruses, by reducing the report time from three days to six hours. The clinical application prospect of nanopore sequencing technology is promising in the pathogen diagnosis of LRTI.